MarketPulse

Exact Sciences acquisition

6 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Abbott Laboratories Stock Slumps 30%; Analysts Eye Dividend King Opportunity

Abbott Laboratories ($ABT) slides 30% amid slower nutrition and diagnostics growth, but Dividend King status and $21B Exact Sciences deal attract value investors.
ABThealthcarelong-term investing
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Abbott vs. Dexcom: Which CGM Leader Offers Better Value in 2024?

Abbott offers diversified healthcare exposure with dividend income; Dexcom provides pure CGM growth but faces GLP-1 drug competition and concentration risk.
ABTDXCMdividend stockshealthcare stocks
Investing.comInvesting.com··Thomas Hughes

Abbott Stock Plunges 45% But Analysts See Swift Rebound on Oversold Technicals

Abbott (ABT) crashed 45% on weak Q4 guidance but analyst bullishness, institutional accumulation, and oversold technicals suggest rapid recovery potential.
ABTtechnical analysisinstitutional buying
The Motley FoolThe Motley Fool··Eric Volkman

Abbott Slashes 2026 Guidance After Q1 Beat, Exact Sciences Deal Weighs on Stock

Abbott met Q1 expectations with $11.2B revenue but cut full-year EPS guidance due to share dilution from Exact Sciences acquisition, triggering 6% stock decline.
ABTguidance cutmedical devices
BenzingaBenzinga··Vandana Singh

Abbott Labs Beats Q1 But Slashes 2026 Guidance, Stock Tumbles 4.76%

Abbott Labs beat Q1 earnings but slashed full-year guidance, causing stock to plummet 4.76% to 52-week low of $96.72.
ABTstock declineearnings beat
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Abbott Labs Stock Slides 22% on Weak Diagnostics, But Dividend Investors See Opportunity

$ABT down 22% after disappointing earnings, but strong medical devices and $21B Exact Sciences deal offer recovery potential for income seekers.
ABTEXAShealthcaredividend stock